Literature DB >> 8402575

Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells.

P Perego1, G Casati, R A Gambetta, C Soranzo, F Zunino.   

Abstract

The effect of modulation of protein kinase C (PKC) activity by 12-O-tetradecanoylphorbol-13-acetate (TPA) on cisplatin cytotoxicity was examined in a human osteosarcoma U2-OS cell line and in a U2-OS variant (U2-OS/Pt) selected after continuous exposure to increasing concentrations of cisplatin. U2-OS/Pt cells showed a 7.5-fold resistance to the drug. A 24 h exposure of cells to TPA caused a potentiation of cisplatin cytotoxicity in sensitive and in resistant cells; under these conditions, PKC activity was shown to be down-regulated. In contrast, a short-term exposure of cells to TPA did not affect cisplatin cytotoxicity in U2-OS or in U2-OS/Pt cells. These results support the involvement of PKC in cellular response to cisplatin. However, this enzyme is probably not directly implicated in the mechanisms of acquired resistance in this cell system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402575     DOI: 10.1016/0304-3835(93)90010-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Amputation and dexniguldipine as treatment for canine appendicular osteosarcoma.

Authors:  K A Hahn; A M Legendre; H M Schuller
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.

Authors:  Anna C Pavlick; Jennifer Wu; John Roberts; Mark A Rosenthal; Anne Hamilton; Scott Wadler; Kathleen Farrell; Michelle Carr; David Fry; Anthony J Murgo; Ruth Oratz; Howard Hochster; Leonard Liebes; Franco Muggia
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-17       Impact factor: 3.333

3.  Nucleolar targeting by platinum: p53-independent apoptosis follows rRNA inhibition, cell-cycle arrest, and DNA compaction.

Authors:  Erica J Peterson; Vijay R Menon; Laura Gatti; Ralph Kipping; Dilhara Dewasinghe; Paola Perego; Lawrence F Povirk; Nicholas P Farrell
Journal:  Mol Pharm       Date:  2014-12-03       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.